R&D News | pharmaphorum

News

Almirall signs $210m bispecifics deal with EpimAb

A few months after raising €200 million in investment capital to boost its pipeline, Spanish drugmaker Almirall has used some of the cash for a bispecific antibody partner

News

MHRA pledges two-week review for low-risk clinical trials

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has implemented one part of its plan to reform the regulations governing clinical trials, namely an ini

News

Incyte’s oral vitiligo drug heading for phase 3

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in pati

News

Faron’s Clever-1 drug shows promise in blood cancers

Faron Pharmaceuticals has reported data from a phase 1/2 trial pointing to the potential of its macrophage-directed antibody bexmarilimab as a treatment for blood cancers

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

Sanofi partners BioMap on AI hunt for biologic therapies

Sanofi has added another dimension to the use of artificial intelligence (AI) to seek out new drugs, partnering with BioMap on a project to find biologic therapies in a de

Almirall signs $210m bispecifics deal with EpimAb

MHRA pledges two-week review for low-risk clinical trials

Incyte’s oral vitiligo drug heading for phase 3

Faron’s Clever-1 drug shows promise in blood cancers

Novo Nordisk’s semaglutide aces another outcomes trial

Sanofi partners BioMap on AI hunt for biologic therapies

Data builds on Roche's dominance in primary progressive MS

How to meet your physicians where they are online

News

Editor's Picks